Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

C. P. Belani, Avi Israel Einzig, P. Bonomi, T. Dobbs, M. J. Capozzoli, R. Earhart, L. J. Cohen, J. D. Luketich

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and efficacy of docetaxel and carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC of 6 mg/ml/min (Calvert's formula) every three weeks. Patients also received dexamethasone 8 mg orally twice daily for three days beginning one day before each docetaxel treatment. Filgrastim was not allowed during the first cycle and was added only if a patient experienced febrile neutropenia or grade 4 neutropenia lasting ≥ 7 days. Results: There were 1 complete and 11 partial responses for an objective response rate of 43% (95% CI: 24%-63%) in 28 evaluable patients and 36% (95% CI: 20%-55%) in the intent-to-treat population. The median duration of response was 5.5 months (range 3.0-12.5 months). The median survival was 13.9 months (range 1-35+ months); one-year survival was 52%. The most common toxicity was hematologic, which included grade 4 neutropenia (79% of patients and 7% percent of cycles) and febrile neutropenia (15% of patients); there were no episodes of grade 3 or 4 infection. The most common severe nonhematologic toxicities were asthenia (24%) and myalgia (12%); there were no grade 3 or 4 neurologic effects. Conclusions: The combination of docetaxel and carboplatin has an acceptable toxicity profile and is active in the treatment of previously untreated patients with advanced NSCLC. This combination is being evaluated in a randomized phase III trial involving patients with advanced and metastatic NSCLC.

Original languageEnglish (US)
Pages (from-to)673-678
Number of pages6
JournalAnnals of Oncology
Volume11
Issue number6
DOIs
StatePublished - Nov 15 2000

Fingerprint

docetaxel
Carboplatin
Non-Small Cell Lung Carcinoma
Febrile Neutropenia
Neutropenia
Asthenia
Survival
Myalgia

Keywords

  • Carboplatin
  • Docetaxel
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. / Belani, C. P.; Einzig, Avi Israel; Bonomi, P.; Dobbs, T.; Capozzoli, M. J.; Earhart, R.; Cohen, L. J.; Luketich, J. D.

In: Annals of Oncology, Vol. 11, No. 6, 15.11.2000, p. 673-678.

Research output: Contribution to journalArticle

Belani, CP, Einzig, AI, Bonomi, P, Dobbs, T, Capozzoli, MJ, Earhart, R, Cohen, LJ & Luketich, JD 2000, 'Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer', Annals of Oncology, vol. 11, no. 6, pp. 673-678. https://doi.org/10.1023/A:1008342116536
Belani, C. P. ; Einzig, Avi Israel ; Bonomi, P. ; Dobbs, T. ; Capozzoli, M. J. ; Earhart, R. ; Cohen, L. J. ; Luketich, J. D. / Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. In: Annals of Oncology. 2000 ; Vol. 11, No. 6. pp. 673-678.
@article{eca286075b0f4082ba37f0ad224ca7e0,
title = "Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer",
abstract = "Purpose: To evaluate the safety and efficacy of docetaxel and carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC of 6 mg/ml/min (Calvert's formula) every three weeks. Patients also received dexamethasone 8 mg orally twice daily for three days beginning one day before each docetaxel treatment. Filgrastim was not allowed during the first cycle and was added only if a patient experienced febrile neutropenia or grade 4 neutropenia lasting ≥ 7 days. Results: There were 1 complete and 11 partial responses for an objective response rate of 43{\%} (95{\%} CI: 24{\%}-63{\%}) in 28 evaluable patients and 36{\%} (95{\%} CI: 20{\%}-55{\%}) in the intent-to-treat population. The median duration of response was 5.5 months (range 3.0-12.5 months). The median survival was 13.9 months (range 1-35+ months); one-year survival was 52{\%}. The most common toxicity was hematologic, which included grade 4 neutropenia (79{\%} of patients and 7{\%} percent of cycles) and febrile neutropenia (15{\%} of patients); there were no episodes of grade 3 or 4 infection. The most common severe nonhematologic toxicities were asthenia (24{\%}) and myalgia (12{\%}); there were no grade 3 or 4 neurologic effects. Conclusions: The combination of docetaxel and carboplatin has an acceptable toxicity profile and is active in the treatment of previously untreated patients with advanced NSCLC. This combination is being evaluated in a randomized phase III trial involving patients with advanced and metastatic NSCLC.",
keywords = "Carboplatin, Docetaxel, Non-small-cell lung cancer",
author = "Belani, {C. P.} and Einzig, {Avi Israel} and P. Bonomi and T. Dobbs and Capozzoli, {M. J.} and R. Earhart and Cohen, {L. J.} and Luketich, {J. D.}",
year = "2000",
month = "11",
day = "15",
doi = "10.1023/A:1008342116536",
language = "English (US)",
volume = "11",
pages = "673--678",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

AU - Belani, C. P.

AU - Einzig, Avi Israel

AU - Bonomi, P.

AU - Dobbs, T.

AU - Capozzoli, M. J.

AU - Earhart, R.

AU - Cohen, L. J.

AU - Luketich, J. D.

PY - 2000/11/15

Y1 - 2000/11/15

N2 - Purpose: To evaluate the safety and efficacy of docetaxel and carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC of 6 mg/ml/min (Calvert's formula) every three weeks. Patients also received dexamethasone 8 mg orally twice daily for three days beginning one day before each docetaxel treatment. Filgrastim was not allowed during the first cycle and was added only if a patient experienced febrile neutropenia or grade 4 neutropenia lasting ≥ 7 days. Results: There were 1 complete and 11 partial responses for an objective response rate of 43% (95% CI: 24%-63%) in 28 evaluable patients and 36% (95% CI: 20%-55%) in the intent-to-treat population. The median duration of response was 5.5 months (range 3.0-12.5 months). The median survival was 13.9 months (range 1-35+ months); one-year survival was 52%. The most common toxicity was hematologic, which included grade 4 neutropenia (79% of patients and 7% percent of cycles) and febrile neutropenia (15% of patients); there were no episodes of grade 3 or 4 infection. The most common severe nonhematologic toxicities were asthenia (24%) and myalgia (12%); there were no grade 3 or 4 neurologic effects. Conclusions: The combination of docetaxel and carboplatin has an acceptable toxicity profile and is active in the treatment of previously untreated patients with advanced NSCLC. This combination is being evaluated in a randomized phase III trial involving patients with advanced and metastatic NSCLC.

AB - Purpose: To evaluate the safety and efficacy of docetaxel and carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC of 6 mg/ml/min (Calvert's formula) every three weeks. Patients also received dexamethasone 8 mg orally twice daily for three days beginning one day before each docetaxel treatment. Filgrastim was not allowed during the first cycle and was added only if a patient experienced febrile neutropenia or grade 4 neutropenia lasting ≥ 7 days. Results: There were 1 complete and 11 partial responses for an objective response rate of 43% (95% CI: 24%-63%) in 28 evaluable patients and 36% (95% CI: 20%-55%) in the intent-to-treat population. The median duration of response was 5.5 months (range 3.0-12.5 months). The median survival was 13.9 months (range 1-35+ months); one-year survival was 52%. The most common toxicity was hematologic, which included grade 4 neutropenia (79% of patients and 7% percent of cycles) and febrile neutropenia (15% of patients); there were no episodes of grade 3 or 4 infection. The most common severe nonhematologic toxicities were asthenia (24%) and myalgia (12%); there were no grade 3 or 4 neurologic effects. Conclusions: The combination of docetaxel and carboplatin has an acceptable toxicity profile and is active in the treatment of previously untreated patients with advanced NSCLC. This combination is being evaluated in a randomized phase III trial involving patients with advanced and metastatic NSCLC.

KW - Carboplatin

KW - Docetaxel

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033735209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033735209&partnerID=8YFLogxK

U2 - 10.1023/A:1008342116536

DO - 10.1023/A:1008342116536

M3 - Article

VL - 11

SP - 673

EP - 678

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -